CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Seeking Alpha News (Wed, 17-Apr 9:26 AM ET)
FDA approves Alvotech biosimilar of J&J top-selling drug Stelara
Seeking Alpha News (Tue, 16-Apr 6:22 PM ET)
Business Wire (Tue, 16-Apr 5:43 PM ET)
AbbVie to develop long acting injectables in a deal worth up to $1.9B
Seeking Alpha News (Tue, 16-Apr 12:54 PM ET)
AbbVie to develop long-acting injectables in a deal worth up to $1.9B
Seeking Alpha News (Tue, 16-Apr 12:54 PM ET)
Business Wire (Tue, 16-Apr 8:00 AM ET)
AbbVie keeps Humira market share near 100% despite biosimilars: report
Seeking Alpha News (Sat, 13-Apr 10:52 AM ET)
Business Wire (Thu, 11-Apr 8:30 AM ET)
Business Wire (Tue, 9-Apr 4:30 PM ET)
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Teva Pharmaceutical Industries Limited American Depositary Shares trades on the NYSE stock market under the symbol TEVA.
As of April 18, 2024, TEVA stock price declined to $12.78 with 3,984,020 million shares trading.
TEVA has a beta of 0.49, meaning it tends to be less sensitive to market movements. TEVA has a correlation of 0.03 to the broad based SPY ETF.
TEVA has a market cap of $14.48 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries Limited American Depositary Shares reported $4 billion in Revenue and $1.00 earnings per share. This beat revenue expectation by $447 million and exceeded earnings estimates by $.23.
In the last 3 years, TEVA stock traded as high as $14.47 and as low as $6.78.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): RAYD, IEFA, EFA, EFV, IXUS.
TEVA has outperformed the market in the last year with a return of +50.4%, while the SPY ETF gained +22.3%. In the last 3 month period, TEVA beat the market returning +15.9%, while SPY returned +6.1%. However, in the most recent 2 weeks TEVA has underperformed the stock market by returning -9.5%, while SPY returned -3.8%.
TEVA support price is $12.96 and resistance is $13.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA stock will trade within this expected range on the day.